Please login to the form below

Not currently logged in

Novartis' secukinumab tops Enbrel in psoriasis

Data reinforces secukinumab's position among new generation of biologic

Studies published in the New England Journal of Medicine (NEJM) suggest Novartis' interleukin-17A (IL-17A) inhibitor secukinumab outperforms the most widely-used biologic drug for plaque psoriasis.  

The data reinforces secukinumab's position among new generation of biologic drugs that promise to improve on older tumour necrosis factor (TNF)-blocking therapies like Pfizer's $9bn-a-year Enbrel (etanercept).  

One of phase III trials published in the NEJM - called FIXTURE - compared secukinumab directly to Enbrel and found that Novartis' drug was significantly more effective in clearing the skin lesions that characterise the condition.  

More than half of the secukinumab-treated patients achieved total or near-total clearance of their psoriasis lesions after 12 weeks' treatment, compared to just 21 per cent of the Enbrel-treated group.  

Patients on the IL-17A inhibitor continued to improve as treatment continued, with around 70 per cent having clear or almost clear skin right through to the end of the year-long trial. They also reported significantly better improvements in other symptoms such as itching, pain and scaling compared to Enbrel.  

Secukinumab has been filed for approval in Europe, the US and Japan and could be in a position to launch the drug later this year or early in 2015. Analysts at Evaluate Pharma have predicted the drug could achieve sales of around $570m by 2018.  

In fact, along with other new treatments for psoriasis such as AstraZeneca/Amgen's brodalumab, Lilly's ixekizumab, Celgene's apremilast, secukinumab is expected to drive rapid growth in the global psoriasis market from a level of around $6bn in 2012 to almost $9bn by 2023, according to market research firm Visiongain.  

Like secukinumab, brodalumab and ixekizumab both target IL-17 and are being positioned in the first instance as targeted drugs that can be used in the 50 per cent or so of patients who fail to get adequate relief using current therapies.  

While the new biologics are raising the bar for treatment of moderate-to-severe plaque psoriasis, there is still a pressing need for improved therapies for milder cases of the disease where the role of expensive, injectable biologic drugs is harder to establish.  

Apremilast is particularly interesting in that regard, as it is a small molecule inhibitor of type-4 cyclic nucleotide phosphodiesterase and can be dosed orally, with what appears to be a benign safety profile compared to other psoriasis treatments.  

Apremilast was approved in the US in March with the brand name Otezla for psoriatic arthritis and could add a plaque psoriasis indication later this year.

Article by
Phil Taylor

10th July 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...